Matthew D'Costa
@matthewdcostamd
ID: 1142107069862035456
21-06-2019 16:28:39
445 Tweet
238 Followers
227 Following
Clinical trials have shown remarkable benefits of SGLT-2 inhibitors. This collection from JASN, @CJASN, & ASN Kidney360 highlights rapidly advancing knowledge of SGLT-2 inhibitor benefits, risks, mechanisms of action, & clinical application bit.ly/ASNSGLT2 #jnlcoll
Excited to share our update on CMV in the transplant setting: Where are we now and what happens next? A report from the International CMV Symposium 2021. Join us for the next symposium in Barcelona, May 2023! High impact learning, terrific speakers. onlinelibrary.wiley.com/doi/full/10.11…
7 ways the EMPA-KIDNEY trial will impact clinical care in CKD A Thread 🧵 Sources NEJM Nephrology Journal Club Diabetes Canada American Diabetes Association KDIGO European Society of Cardiology Journals Swapnil Hiremath @hswapnil.medsky.social Joel M. Topf, MD FACP
It was a such a pleasure to meet Krista Lentine, MD,PhD | FASN | FAST at Kidney Week!!
Clinicopathologic Characteristics, Etiologies, and Outcome of Secondary Oxalate Nephropathy - Mayo Clinic Proceedings mayoclinicproceedings.org/article/S0025-… Mayo Clinic Pathology Mayo Clinic Nephrology Renal Pathology Society #renalpath
Genetic testing in nephrology is becoming increasingly important to diagnose patients. This Review proposes an algorithm for the assessment of variant of uncertain significance and how some can be reassigned to a diagnostic grouping bit.ly/KID0298 Abinet Aklilu
I’ve been too quiet lately due to a busy work and life schedule. I am finally taking time to visit the USA and go to the Mayo Clinic nephrology update course in San Diego this week :) Mayo Clinic Nephrology looking forward to seeing my colleagues, mentors and friends !